Join Ansys and Intel on November 10 to gain insight into how you can optimize your hardware and software deployments for best performance
Webcasts
28 September 2020
AI technologies being developed today will lead to new capabilities tomorrow and enable new business applications the day after.
15 September 2020
Now, more than ever, there is a growing need for integration and optimization in the laboratory.
30 March 2020
Learn the benefits of a cloud-based LIMS solution by taking a look into the journey of Thermo Scientific SampleManager LIMS software customers who have transitioned to or implemented a cloud-based solution in their laboratory.
21 January 2020
This webcast will provide insights on how scientists and research organisations are using, or planning to use, cloud technologies, to advance their groundbreaking research
Latest issue
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
